The popular weight-loss and diabetes drugs known as GLP-1 receptor agonists may do something their makers never set out to do: protect the heart from its most common rhythm disorder.
According to research presented at Heart Rhythm 2026, an annual meeting of heart-rhythm specialists, a study of more than 13,000 patients who started a GLP-1 drug found they were significantly less likely to develop atrial fibrillation — the irregular, often racing heartbeat that raises the risk of stroke and heart failure — than a matched group who did not take one. They also lived longer.
The surprise was in the fine print. The lower AFib risk held regardless of how much weight patients lost, and in some cases even among those who gained weight — a sign the drugs may steady the heart through some pathway beyond slimming down. Among the medicines studied, semaglutide showed the strongest effect, and patients over 65 saw the largest benefit, a drop of roughly 44 percent.
Atrial fibrillation affects more than 40 million people worldwide and is behind an estimated 454,000 U.S. hospitalizations a year. The study’s lead author, University of Virginia cardiologist Kenneth Bilchick, told Healio the results were better than expected.
Allyson Good curates senior living, health, and family content. She is formerly the Managing Editor of Active Life, a print newspaper published in 2016-2017 for seniors, choosing practical articles on health, money, safety, and everyday living for older readers. She is also an avid gardener and offers up Garden Hints and Tips on a regular basis.